



Notice Concerning Syndicated Loan Agreement

Nagoya, Japan, March 8, 2024 – RaQualia Pharma Inc. (headquartered in Nagoya; President & CEO: Hirobumi Takeuchi, “RaQualia”) announced today that its Board of Directors has resolved to enter into a syndicate loan agreement with a group of financial institutions as follows:

1. Purpose of the syndicated loan

The syndicated loan is intended to procure funds for acquiring shares of FIMECS, inc., as announced in the “Acquisition of FIMECS by RaQualia Pharma” dated February 14, 2024.

2. Outline of the syndicated loan

| | |
|---------------------------|--|
| Lenders | Syndicate led by Mizuho Bank, Ltd. as arranger and The Shoko Chukin Bank, Ltd. as co-arranger |
| Loan amount | 3.5 billion yen |
| Date of execution | March 25, 2024 (scheduled) |
| Loan term | Seven years (84 months) |
| Interest rate | Base rate + spread |
| Repayment | Initial payment on June 30, 2024, followed by equal principal payments every three months thereafter |
| Collateral | Shares of FIMECS, inc. and special debt guarantee |
| Major financial covenants | From the fiscal year ending December 2024 onwards, the EBITDA calculated based on the figures presented in the consolidated income statement for each fiscal year shall not be negative for two consecutive periods. [Note: EBITDA calculation formula: Operating Profit + Depreciation and Amortization Expenses] |

3. Future Outlook

The impact of the syndicated loan on the consolidated financial results for the fiscal year ending December 31, 2024 (January 1, 2024 to December 31, 2024) is incorporated in the consolidated earnings forecast for the fiscal year ending December 31, 2024 (January 1, 2024 to December 31, 2024), which was disclosed on February 14, 2024.